{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:44:19Z","timestamp":1793659459077,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical and Biological Laboratories Co., Ltd."},{"name":"Agency for Medical Research and Development","award":["22ek0109566"],"award-info":[{"award-number":["22ek0109566"]}]},{"name":"Agency for Medical Research and Development","award":["22ek0109566"],"award-info":[{"award-number":["22ek0109566"]}]},{"name":"Agency for Medical Research and Development","award":["22ek0109566"],"award-info":[{"award-number":["22ek0109566"]}]},{"name":"Agency for Medical Research and Development","award":["22ek0109566"],"award-info":[{"award-number":["22ek0109566"]}]},{"name":"Agency for Medical Research and Development","award":["22ek0109566"],"award-info":[{"award-number":["22ek0109566"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A serum biomarker for diagnosing ulcerative colitis (UC) remains to be established. Although we recently reported an anti-integrin \u03b1v\u03b26 antibody (V6 Ab) for diagnosing UC with high sensitivity and specificity, no large-scale validation study exists. This study aimed to validate the diagnostic value of V6 Ab for UC using a nationwide multicenter cohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We measured V6 Ab titers in patients definitively diagnosed with UC, Crohn\u2019s disease (CD), or other gastrointestinal disorders (OGDs). The primary outcome was the diagnostic value of V6 Ab. Secondary outcomes were factors associated with false-negative results in patients with UC and false-positive results in patients without UC and the heterogeneity of the diagnostic value of V6 Ab among the participating facilities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 1241, 796, and 206 patients with UC, CD, and OGD, respectively, from 28 Japanese high-volume referral centers. The diagnostic sensitivity of V6 Ab for UC was 87.7%, and its specificities for CD and OGDs were 82.0% and 87.4%, respectively. Multivariable logistic regression analysis showed that false-negative results were associated with older age at the time of sample collection, current smokers, lower partial Mayo score, and not receiving advanced therapies in patients with UC, and false-positive results were associated with colonic CD in patients with CD. No factor was associated with false-positive results in patients with OGDs. There were no significant differences in the diagnostic value of V6 Ab among the centers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The diagnostic value of V6 Ab for UC was validated in the large-scale nationwide multicenter study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-024-02176-x","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:21:47Z","timestamp":1732796507000},"page":"86-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-integrin \u03b1v\u03b26 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study"],"prefix":"10.1007","volume":"60","author":[{"given":"Makoto","family":"Okabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shiokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kitamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Uza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ohmiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiko","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Kunisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukunori","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Torisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kanmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Narimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Honzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Seno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417\u201329.","journal-title":"N Engl J Med"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756\u201370.","journal-title":"Lancet"},{"key":"2176_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2176_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144\u201364.","journal-title":"J Crohns Colitis"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","volume":"160","author":"T Kuwada","year":"2021","unstructured":"Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti-integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis. Gastroenterology. 2021;160:2383-2394.e21.","journal-title":"Gastroenterology"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1242\/jcs.108.6.2241","volume":"108","author":"JM Breuss","year":"1995","unstructured":"Breuss JM, Gallo J, DeLisser HM, et al. Expression of the beta 6 integrin subunit in development, neoplasia, and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108:2241\u201351.","journal-title":"J Cell Sci"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cbin.10258","volume":"38","author":"Y Yu","year":"2014","unstructured":"Yu Y, Chen S, Lu GF, et al. Alphavbeta6 is required in maintaining the intestinal epithelial barrier function. Cell Biol Int. 2014;38:777\u201381.","journal-title":"Cell Biol Int"},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1053\/j.gastro.2022.06.026","volume":"163","author":"Y Muramoto","year":"2022","unstructured":"Muramoto Y, Nihira H, Shiokawa M, et al. Anti-integrin \u03b1v\u03b26 antibody as a diagnostic marker for pediatric patients with ulcerative colitis. Gastroenterology. 2022;163:1094-1097.e14.","journal-title":"Gastroenterology"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/jcm11071881","volume":"11","author":"N Rydell","year":"2022","unstructured":"Rydell N, Ekoff H, Hellstr\u00f6m PM, Mov\u00e9rare R. Measurement of serum IgG anti-integrin \u03b1v\u03b26 autoantibodies is a promising tool in the diagnosis of ulcerative colitis. J Clin Med. 2022;11:1881.","journal-title":"J Clin Med"},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos AE, Dunn A, Fischer J, et al. Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology. 2023;164:619\u201329.","journal-title":"Gastroenterology"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","volume":"28","author":"M Uzzan","year":"2022","unstructured":"Uzzan M, Martin JC, Mesin L, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022;28:766\u201379.","journal-title":"Nat Med"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","volume":"56","author":"I Marafini","year":"2024","unstructured":"Marafini I, Laudisi F, Salvatori S, et al. Diagnostic value of anti-integrin \u03b1v\u03b26 antibodies in ulcerative colitis. Dig Liver Dis. 2024;56:55\u201360.","journal-title":"Dig Liver Dis"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"2176_CR15","unstructured":"Anti-integrin \u03b1v\u03b26 ELISA kit. https:\/\/www.mblbio.com\/bio\/dtl\/dtlfiles\/5288_240701.pdf. Accessed 18 Nov 2024."},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut"},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;1:514.","journal-title":"Lancet"},{"key":"2176_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ajg.2015.6","volume":"110","author":"SB Menees","year":"2015","unstructured":"Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of c-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444\u201354.","journal-title":"Am J Gastroenterol"},{"key":"2176_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208974","volume":"13","author":"MP Horn","year":"2018","unstructured":"Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn\u2019s disease. PLoS ONE. 2018;13: e0208974.","journal-title":"PLoS ONE"},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.cgh.2021.12.035","volume":"21","author":"Y Kakuta","year":"2023","unstructured":"Kakuta Y, Shirai T, McGovern DPB, Braun J, Fujii H, Masamune A. Novel diagnostic autoantibodies against endothelial protein C receptor in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2023;21:844\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00535-019-01580-y","volume":"54","author":"M Higashiyama","year":"2019","unstructured":"Higashiyama M, Sugita A, Koganei K, et al. Management of elderly ulcerative colitis in Japan. J Gastroenterol. 2019;54:571\u201386.","journal-title":"J Gastroenterol"},{"key":"2176_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ecco-jcc\/jjx002.490","volume":"11","author":"A Sturm","year":"2017","unstructured":"Sturm A, Maaser C, Mendall M, et al. European Crohn\u2019s and colitis organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11:263\u201373.","journal-title":"J Crohns Colitis"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev-cellbio-011620-034148","volume":"36","author":"D Frasca","year":"2020","unstructured":"Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB. B cell immunosenescence. Annu Rev Cell Dev Biol. 2020;36:551\u201374.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4065\/81.11.1462","volume":"81","author":"SS Mahid","year":"2006","unstructured":"Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462\u201371.","journal-title":"Mayo Clin Proc"},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/j.1572-0241.2007.01265.x","volume":"102","author":"O H\u00f6ie","year":"2007","unstructured":"H\u00f6ie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692\u2013701.","journal-title":"Am J Gastroenterol"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13278","volume":"125","author":"T Nesrin","year":"2019","unstructured":"Nesrin T, Ian T, Patrick JT, Lucy CF. Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: an investigation and review. Basic Clin Pharmacol Toxicol. 2019;125:474\u201383.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","volume":"387","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156\u201367.","journal-title":"Lancet"},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","volume":"58","author":"H Yoshida","year":"2023","unstructured":"Yoshida H, Shiokawa M, Kuwada T, et al. Anti-integrin \u03b1v\u03b26 autoantibodies in patients with primary sclerosing cholangitis. J Gastroenterol. 2023;58:778\u201389.","journal-title":"J Gastroenterol"}],"updated-by":[{"DOI":"10.1007\/s00535-024-02203-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02176-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02176-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02176-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:04:59Z","timestamp":1736427899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02176-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02176-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00535-024-02203-x","URL":"https:\/\/doi.org\/10.1007\/s00535-024-02203-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masahiro Shiokawa received patent royalties and research grants from Medical and Biological Laboratories Co., Ltd. Tadakazu Hisamatsu received consulting fees from Mitsubishi Tanabe Pharma Co., EA Pharma Co., Abbvie GK., Janssen Pharmaceutical K.K, Nichi-Iko Pharmaceutical Co., Ltd., Eli Lilly, and Gilead Sciences Inc., honorariums from Mitsubishi Tanabe Pharma Co., Abbvie GK., EA Pharma Co., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Kissei Pharmaceutical Co., Ltd., and research grants from EA Pharma Co., Abbvie GK., Pfizer Inc., Mitsubishi Tanabe Pharma Co., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co. Ltd., and Boston Scientific Corporation. Hajime Yamazaki received research grants from Takeda Pharmaceutical Co., Ltd. Aki Sakatani received endowed chair from Toukeikai Kyoritsu Hospital. Toshimitsu Fujii received honorariums from Abbvie GK., Janssen Pharmaceutical K.K, Mitsubishi Tanabe Pharma Co. and Takeda Pharmaceutical Co., Ltd., and research grants from Abbvie GK., Alfresa Pharma Co., Boehringer Ingelheim co., Bristol-Myers Squibb, Celgene Inc., Celltrion Inc., EA Pharma Co., Eli Lilly Japan K.K., Gilead Sciences Inc., Janssen Pharmaceutical KK., Kissei Pharmaceutical Co., Ltd., Mebix Inc., Sanofi Ltd., and Takeda Pharmaceutical Co., Ltd. Minoru Matsuura received honorariums from Janssen Pharmaceutical K.K., and Abbvie GK. Reiko Kunisaki received honorariums from Abbvie GK., Janssen Pharmaceutical K.K, Mitsubishi Tanabe Pharma Co., and Takeda Pharmaceutical Co., Ltd., and research grants from Eli Lilly Japan K.K., Janssen Pharmaceutical K.K, and Takeda Pharmaceutical Co., Ltd. Tomohisa Takagi received honorariums from Janssen Pharmaceutical K.K, Mitsubishi Tanabe Pharma Co., Towa Pharmaceutical Co., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Abbvie GK., EA Pharma Co., Ltd., and Pfizer Japan Inc., research grants from PreMedia Inc., and scholarship grants from Mitsubishi Tanabe Pharma Co. Tetsuo Takehara received honorariums from Abbvie GK., Gilead Sciences Inc., research grants from Gilead Sciences Inc., Janssen Pharmaceutical K.K, and scholarship grants from Abbvie GK., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., and Nippon Kayaku Co., Ltd. Fumihito Hirai received honorariums from Abbvie GK., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., and Takeda Pharmaceutical Co., Ltd., research grants from Eli Lilly Japan K.K., Janssen Pharmaceutical K.K, and Abbvie GK., and scholarship grants from Abbvie GK., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Co. Motohiro Esaki received honorariums from Abbvie GK., Mitsubishi Chemical Group Co., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. Hiroshi Nakase received honorariums from Abbvie GK., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Janssen Pharmaceutical K.K, Gilead Sciences Inc., Pfizer Inc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., VIATRIS Inc, and JIMRO Co., Ltd., research grants from Abbvie GK. and Hoya group Pentax Medical, scholarship grants from Nippon Kayaku Co., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co. and EA Pharma Co., Ltd., and endowed chair from Miyarisan Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kyorin Pharmaceutical Co., Ltd. Katsuyoshi Matsuoka received honorariums from Mitsubishi Tanabe Pharma Co., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Abbvie GK, EA Pharma Co., Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Gilead Sciences, and Eli Lilly Japan K.K., research grants from Janssen Pharmaceutical K.K., and scholarship grants from Mochida Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd. Kaoru Yokoyama received honorariums from Abbvie GK, EA Pharma Co., Ltd., Gilead Sciences Inc., and Takeda Pharmaceutical Co., Ltd. Makoto Naganuma received honorariums from EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical KK., Abbvie GK., JIMRO Co., Ltd., Pfizer Inc., Gilead Sciences Inc., and Takeda Pharmaceutical Co., Ltd., research grants from Kyorin Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Co., Abbvie GK., and Miyarisan Pharmaceutical Co., Ltd., and fees paid for writing a pamphlet from Alfresa Pharma Co. Ltd., Masayuki Saruta received honorariums from Abbvie GK., Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Gilead Sciences Inc., Janssen Pharmaceutical K.K, Kissei Pharmaceutical Co., Ltd., Viatris Pharmaceutical Co., Ltd., and Nobel Pharma Co. Ltd., research grants from Abbvie GK. CMO Co. Ltd. and PPD-SNBL KK., and scholarship grants from Abbvie GK., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kissei Pharmaceutical Co., Ltd. Hiroshi Seno received honorariums from Eisai Co., Ltd., and scholarship grants from Mitsubishi Tanabe Pharma Co. All other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}